UPDATE: Oxygen Biotherapeutics Reports Deal to Buy Phase 3, FDA Fast-Track Designated Levosimendan from Phyxius Pharma

Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT ) a developer of oxygen-carrying therapeutics, today announced it has signed a Definitive Agreement (“Agreement”) to acquire certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output